HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Over the last 12 months, insiders at HOOKIPA Pharma Inc. have bought $0 and sold $0 worth of HOOKIPA Pharma Inc. stock.
On average, over the past 5 years, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $3.92M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $5,075 was made by Kandera Reinhard (Chief Financial Officer) on 2023‑08‑21.
2023-08-21 | Chief Financial Officer | 7,000 0.0091% | $0.72 | $5,075 | -7.79% | |||
2023-08-16 | Chief Financial Officer | 8,000 0.0103% | $0.71 | $5,712 | -5.67% | |||
2023-07-11 | Chief Executive Officer | 5,000 0.007% | $0.83 | $4,142 | -14.57% | |||
2023-07-07 | Chief Executive Officer | 5,000 0.0068% | $0.81 | $4,050 | -14.50% | |||
2023-07-05 | Chief Executive Officer | 5,000 0.0071% | $0.89 | $4,450 | -18.79% | |||
2023-07-03 | Chief Executive Officer | 5,000 0.0072% | $0.89 | $4,456 | -16.94% | |||
2023-06-30 | Chief Financial Officer | 12,000 0.0166% | $0.88 | $10,560 | -19.15% | |||
2021-12-21 | Sale | Chief Medical Officer | 14,949 0.0457% | $2.49 | $37,223 | -37.90% | ||
2021-04-21 | Sale | 10 percent owner | 328,620 0.9448% | $11.60 | $3.81M | -58.05% | ||
2021-03-29 | Sale | 10 percent owner | 36,829 0.1234% | $13.67 | $503,570 | -54.96% | ||
2021-03-26 | Sale | 10 percent owner | 35,171 0.1167% | $13.69 | $481,642 | -54.91% | ||
2021-03-25 | Sale | 10 percent owner | 28,546 0.093% | $13.12 | $374,569 | -53.55% | ||
2021-03-24 | Sale | 10 percent owner | 52,690 0.1841% | $13.70 | $721,616 | -52.05% | ||
2021-03-23 | Sale | 10 percent owner | 40,000 0.1374% | $13.91 | $556,476 | -53.53% | ||
2021-03-22 | Sale | 10 percent owner | 40,534 0.1369% | $14.54 | $589,263 | -55.71% | ||
2021-03-19 | Sale | 10 percent owner | 166,230 0.5544% | $14.60 | $2.43M | -56.39% | ||
2020-12-17 | Sale | Chief Medical Officer | 27,979 0.1031% | $11.74 | $328,343 | -20.23% | ||
2020-12-16 | Sale | Chief Medical Officer | 380 0.0014% | $11.70 | $4,446 | -18.84% | ||
2020-10-02 | Sale | 10 percent owner | 300 0.0011% | $10.00 | $3,000 | +13.55% | ||
2020-09-15 | Sale | 10 percent owner | 41,597 0.1949% | $12.61 | $524,477 | +5.48% |
SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3177574 32.9111% | $2.54 | 1 | 12 | <0.0001% |
Forbion Capital Fund II Cooperatief U.A. | 10 percent owner | 2494173 25.8329% | $2.54 | 1 | 0 | <0.0001% |
BAKER BROS. ADVISORS LP | 820729 8.5005% | $2.54 | 1 | 0 | <0.0001% | |
Matushansky Igor | Chief Medical Officer | 80178 0.8304% | $2.54 | 0 | 6 | |
Aldag Jorn | Chief Executive Officer | 71952 0.7452% | $2.54 | 4 | 0 | <0.0001% |
Kandera Reinhard | Chief Financial Officer | 43092 0.4463% | $2.54 | 3 | 0 | <0.0001% |
Lilja Anders | Sr. VP, Technical Development | 0 0% | $2.54 | 0 | 1 | |
Orlinger Klaus | Sr. VP, Research | 0 0% | $2.54 | 0 | 3 |
Baker Bros Advisors LP | $5.79B | 82.14 | 8.13M | 0% | +$0 | 41.56 | |
Artal Group S A | $4.03B | 57.27 | 5.67M | 0% | +$0 | 17.63 | |
Tupelo Capital Management LLC | $3.93B | 55.76 | 5.52M | 0% | +$0 | 96.35 | |
Ecor1 Capital Llc | $3.27B | 46.44 | 4.6M | 0% | +$0 | 22.96 | |
Fidelity Investments | $2.39B | 33.94 | 3.36M | 0% | +$0 | 0.16 | |
The Vanguard Group | $1.51B | 21.41 | 2.12M | +0.17% | +$2.57M | 0.03 | |
Morgan Stanley | $882.93M | 12.53 | 1.24M | +4.73% | +$39.87M | 0.07 | |
Redmile Group | $757.4M | 10.75 | 1.06M | 0% | +$0 | 7.73 | |
Acadian Asset Management | $627,000.00 | 8.92 | 882,262 | +85.84% | +$289,622.09 | <0.01 | |
Geode Capital Management | $473.33M | 6.72 | 664,610 | +13.49% | +$56.27M | 0.04 | |
Ikarian Capital LLC | $377.91M | 5.36 | 530,776 | 0% | +$0 | 51.95 | |
BlackRock | $205.98M | 2.92 | 289,293 | -1.69% | -$3.55M | <0.01 | |
Renaissance Technologies | $156,000.00 | 2.21 | 218,446 | +15.8% | +$21,281.23 | <0.0001 | |
Royal Bank of Canada | $150M | 2.13 | 210,297 | -4.55% | -$7.16M | 0.04 | |
Susquehanna International Group | $127.66M | 1.81 | 179,295 | New | +$127.66M | 0.13 | |
State Street | $114.06M | 1.62 | 160,190 | 0% | +$0 | 0.01 | |
Northern Trust | $111.66M | 1.59 | 156,830 | +41.3% | +$32.64M | 0.02 | |
Boothbay Fund Management LLC | $83.8M | 1.19 | 117,695 | 0% | +$0 | 2.71 | |
Two Sigma | $67.47M | 0.96 | 94,759 | +491.65% | +$56.06M | 0.1 | |
Bridgeway Capital Management | $62.3M | 0.88 | 87,500 | 0% | +$0 | 0.89 | |
Prudential Financial | $45.99M | 0.65 | 64,600 | New | +$45.99M | 0.07 | |
Xtx Topco Ltd | $43.51M | 0.62 | 61,109 | -42.22% | -$31.79M | 1.06 | |
Tyler Stone Wealth Management | $33.57M | 0.48 | 47,150 | +21.21% | +$5.87M | 13.74 | |
Virtu Financial Llc | $31,000.00 | 0.44 | 43,021 | New | +$31,000.00 | <0.01 | |
Millennium Management LLC | $29.32M | 0.42 | 41,173 | -28.56% | -$11.72M | 0.02 | |
Charles Schwab | $25.84M | 0.37 | 36,285 | 0% | +$0 | 0.01 | |
Two Sigma Advisers LP | $25.35M | 0.36 | 35,600 | New | +$25.35M | 0.04 | |
Hrt Financial Llc | $24,000.00 | 0.35 | 34,870 | New | +$24,000.00 | <0.0001 | |
Jane Street Capital | $18.51M | 0.26 | 26,002 | New | +$18.51M | 0.02 | |
Beacon Pointe Advisors Llc | $16.66M | 0.24 | 23,400 | 0% | +$0 | 0.19 | |
Apella Capital, LLC | $16.64M | 0.2 | 19,783 | 0% | +$0 | 1.18 | |
Group One Trading | $12.39M | 0.18 | 17,404 | 0% | +$0 | 0.16 | |
International Assets Investment Management Llc | $10.13M | 0.14 | 14,000 | 0% | +$0 | 0.03 | |
UBS | $8.84M | 0.13 | 12,408 | +112.43% | +$4.68M | <0.01 | |
Tower Research Capital | $7.44M | 0.11 | 10,451 | +8.51% | +$583,831.21 | 0.07 | |
Bank of America | $4.56M | 0.07 | 6,405 | -0.73% | -$33,468.70 | <0.0001 | |
Advisor Group Holdings Inc | $2.85M | 0.04 | 4,000 | 0% | +$0 | 0.01 | |
Wells Fargo | $390,000.00 | 0.01 | 548 | +1.48% | +$5,693.43 | <0.0001 | |
Northwestern Mutual Wealth Management Co | $71,000.00 | <0.01 | 100 | New | +$71,000.00 | <0.0001 | |
Citigroup | $53,000.00 | <0.01 | 74 | 0% | +$0 | <0.0001 | |
JPMorgan Chase | $10,000.00 | <0.01 | 14 | 0% | +$0 | <0.0001 | |
Truvestments Capital Llc | $18,000.00 | <0.01 | 25 | New | +$18,000.00 | 0.01 |